Mazyar S. Shadman

Hematology
825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 227 publications

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 14, 2026

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 27, 2026

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL.

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL.

Journal: Oncology and therapy
Published: April 21, 2026

Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.

Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.

Journal: Blood advances
Published: April 07, 2026

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.

Indirect Comparison of the Efficacy of Zanubrutinib vs Ibrutinib and Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-Up.

Journal: Advances in therapy
Published: April 01, 2026

"Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL.

"Immunologic dream team": BiTEs periallotransplant to redirect donor lymphocytes toward GVL.

Journal: Blood advances
Published: March 30, 2026

Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma.

Outcomes of Hematopoietic Cell Transplantation in Patients with Plasmablastic Lymphoma.

Journal: Transplantation and cellular therapy
Published: March 20, 2026

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma.

Journal: Blood cancer journal
Published: March 06, 2026

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

Treatment of Follicular Lymphoma With CHOP and Anti-CD20 Therapy: 15-Year Follow-Up of the SWOG S0016 Trial.

Journal: JAMA oncology
Published: February 26, 2026

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome.

Journal: Blood advances
Published: February 18, 2026

Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial.

Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial.

Journal: Current medical research and opinion
Published: February 13, 2026

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Journal: Future oncology (London, England)
Published: January 31, 2026
Showing 1-12 of 227

Last Updated: 09/26/2026